SCHEMBL185875

SCHEMBL185875

Oc1ccccc1COP(O)Cl

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.53
HSPA5 P11021 1/20 0.46
KEAP1 Q14145 1/20 0.42
TSHR P16473 2/20 0.42
CYP2D6 P10635 1/20 0.42
HIF1A Q16665 1/20 0.42
TAAR1 Q96RJ0 1/20 0.41
AKR1B1 P15121 1/20 0.41
CA12 O43570 4/20 0.39
CA2 P00918 4/20 0.39
CA9 Q16790 3/20 0.38
MPO P05164 1/20 0.38
APP P05067 1/20 0.37
KDM4E B2RXH2 1/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL185874 0.86 IDO1 (0.55) IDO1HSPA5KEAP1TSHRCYP2D6
SCHEMBL3507942 0.83 IDO1 (0.57) IDO1HSPA5KEAP1TSHRCYP2D6
SCHEMBL3507940 0.81 IDO1 (0.59) IDO1HSPA5KEAP1TSHRCYP2D6
SCHEMBL497740 0.81 IDO1 (0.50) IDO1HSPA5KEAP1TSHRCYP2D6
SCHEMBL29152360 0.74 IDO1 (0.52) IDO1HSPA5KEAP1TSHRCYP2D6
SCHEMBL11791488 0.74 IDO1 (0.61) IDO1HSPA5KEAP1TSHRCYP2D6
SCHEMBL126999 0.73 IDO1 (0.67) IDO1HSPA5KEAP1TSHRCYP2D6
SCHEMBL28546165 0.72 TSHR (0.48) IDO1TSHRHIF1ACA12CA2
Salicyl Alcohol SCHEMBL8573675 0.72 HSPA5 (0.52) IDO1HSPA5KEAP1TSHRCYP2D6
SCHEMBL7101247 0.72 IDO1 (0.64) IDO1HSPA5KEAP1TSHRCYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 234 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4683927-A1 ALPHA-MODIFIED NUCLEOSIDE TRIPHOSPHATES AND METHOD FOR THEIR SYNTHESIS Illumina, Inc. (US) 2026-01-28 EP claimed
WO-2024196883-A1 ALPHA-MODIFIED NUCLEOSIDE TRIPHOSPHATES AND METHOD FOR THEIR SYNTHESIS ILLUMINA, INC. (US) 2024-09-26 WO claimed
US-11072624-B2 Synthesis of nucleoside 5′-triphosphates and their derivatives SENA RESEARCH, INCORPORATED (US) 2021-07-27 US claimed
CN-106061986-B Novel synthetic oligomers of neisseria meningitidis serogroup X and process for their preparation 默沙东和惠康基金会合资的希勒曼实验室私人有限公司 2020-07-07 CN claimed
CN-106061986-A Novel synthetic oligomers of neisseria meningitis serogroup x and process of preparing them 默沙东和惠康基金会合资的希勒曼实验室私人有限公司 2016-10-26 CN claimed
CN-103314001-B Novel synthesis of nucleoside 5' -triphosphates and their derivatives 塞纳研究股份有限公司 2016-08-17 CN claimed
CN-103314001-A Novel synthesis of nucleoside 5' -triphosphates and their derivatives SENA RES INC 2013-09-18 CN claimed
US-20130158249-A1 Novel Synthesis of Nucleoside 5'-Triphosphates and Their Derivatives SENA RESEARCH, INCORPORATED (US) 2013-06-20 US claimed
WO-2012024625-A2 NOVEL SYNTHESIS OF NUCLEOSIDE 5'-TRIPHOSPHATES AND THEIR DERIVATIVES SENA RESEARCH, INCORPORATED (US) 2012-02-23 WO claimed
WO-2007110624-A2 IMMOBILISED REAGENT UNIVERSITY COURT OF THE UNIVERSITY OFEDINBURGH (GB) 2007-10-04 WO claimed
US-20260146272-A1 ENZYMATIC SYNTHESIS OF MODIFIED NUCLEOSIDE TRIPHOSPHATE ANALOGUES ILLUMINA, INC. (US) 2026-05-28 US disclosed
EP-4683927-A1 ALPHA-MODIFIED NUCLEOSIDE TRIPHOSPHATES AND METHOD FOR THEIR SYNTHESIS Illumina, Inc. (US) 2026-01-28 EP disclosed
US-20250361260-A1 NUCLEOTIDE ANALOGUES SINGULAR GENOMICS SYSTEMS INC (US) 2025-11-27 US disclosed
US-20250346950-A1 TAGGED NUCLEOSIDE COMPOUNDS USEFUL FOR NANOPORE DETECTION Roche Sequencing Solutions, Inc. (US) 2025-11-13 US disclosed
US-12270075-B2 Tagged nucleoside compounds useful for nanopore detection Roche Sequencing Solutions, Inc. (US) 2025-04-08 US disclosed
WO-2002030884-A2 SULFIDE AND DISULFIDE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES ESPERION THERAPEUTICS, INC. (US) 2002-04-18 WO disclosed
WO-2002030860-A2 KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES ESPERION THERAPEUTICS, INC. (US) 2002-04-18 WO disclosed
WO-2000059855-A1 ETHER COMPOUNDS, COMPOSITIONS, AND USES THEREOF ESPERION THERAPEUTICS, INC. (US) 2000-10-12 WO disclosed
WO-1998017281-A1 MONOPHOSPHATE PRODRUGS OF β-L-FD4C AND β-L-FddC AS POTENT ANTIVIRAL AGENTS VION PHARMACEUTICALS, INC. (US) 1998-04-30 WO disclosed
WO-1996041812-A1 OLIGONUCLEOTIDE PHOSPHORYLATION METHOD AND PRODUCTS ISIS INNOVATION LIMITED (GB) 1996-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250346950-A1 TAGGED NUCLEOSIDE COMPOUNDS USEFUL FOR NANOPORE DETECTION PNP, NT5C3B, POLN IDO1 4654/4885HSPA5 4590/4885KEAP1 4679/4885
US-11072624-B2 Synthesis of nucleoside 5′-triphosphates and their derivatives TYMP, PNP, DCTPP1 IDO1 2735/4885HSPA5 2564/4885KEAP1 3993/4885
US-12270075-B2 Tagged nucleoside compounds useful for nanopore detection NT5C3B, PNP, POLN IDO1 4688/4885HSPA5 4473/4885KEAP1 4697/4885
US-20130158249-A1 Novel Synthesis of Nucleoside 5'-Triphosphates and Their Derivatives NUDT1, PNP, TYMP IDO1 2875/4885HSPA5 1975/4885KEAP1 3417/4885
US-20250361260-A1 NUCLEOTIDE ANALOGUES ADAR, NUDT1, NSUN2 IDO1 4209/4885HSPA5 2909/4885KEAP1 4579/4885
US-20260146272-A1 ENZYMATIC SYNTHESIS OF MODIFIED NUCLEOSIDE TRIPHOSPHATE ANALOGUES PNP, NTPCR, NME2 IDO1 4136/4885HSPA5 3113/4885KEAP1 2717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.